Show
Sort by
-
- Journal Article
- A1
- open access
Demographics, disease characteristics, and time to effective treatment of patients with psoriasis in the Ghent PsoPlus cohort of 2021
-
An unexpected high prevalence of Focal Facial Dermal Dysplasia (FFDD) type IV is linked to a founder effect in the Belgian population
-
- Journal Article
- A1
- open access
Response to IL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the IL‐17A gene : results from a multicentre study of four European psoriasis cohorts
-
- Journal Article
- A1
- open access
Defining a minimal effective serum trough concentration of secukinumab in psoriasis : a step toward personalized therapy
-
Developing a therapeutic window for secukinumab in psoriasis : a step towards personalized therapy
-
Developing a therapeutic window for secukinumab in psoriasis : a step towards personalized therapy